Company intelligence / Profile preview

Immunorizon

Ownership: Public · PPBT
Development stage: Preclinical

Overview

Immunorizon developed conditionally activated tri-specific antibodies that engage both T cells and NK cells to mount localized immune responses within the tumor microenvironment. Their lead compound targets the 5T4 antigen and uses cleavable capping technology to confine therapeutic activity to the tumor microenvironment.

Therapeutic areas: Oncology
Modalities: Tri-specific antibodiesMulti-specific T and NK cell engagers
Industry: Biotech

Beyond the preview

Go deeper on Immunorizon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunorizon.

Explore the full profile